These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28350565)

  • 1. Impact of Surgical Approach on Long-term Survival in Esophageal Adenocarcinoma Patients With or Without Neoadjuvant Chemoradiotherapy.
    Noordman BJ; van Klaveren D; van Berge Henegouwen MI; Wijnhoven BPL; Gisbertz SS; Lagarde SM; van der Gaast A; Hulshof MCCM; Biermann K; Steyerberg EW; van Lanschot JJB;
    Ann Surg; 2018 May; 267(5):892-897. PubMed ID: 28350565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands.
    Visser E; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Ann Surg; 2017 Nov; 266(5):863-869. PubMed ID: 28742691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical resection after neoadjuvant chemoradiation for oesophageal adenocarcinoma: what is the optimal timing?
    Ranney DN; Mulvihill MS; Yerokun BA; Fitch Z; Sun Z; Yang CF; D'Amico TA; Hartwig MG
    Eur J Cardiothorac Surg; 2017 Sep; 52(3):543-551. PubMed ID: 28498967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
    Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
    Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of the Circumferential Resection Margin in Esophageal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Hulshoff JB; Faiz Z; Karrenbeld A; Kats-Ugurlu G; Burgerhof JG; Smit JK; Plukker JT
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1301-9. PubMed ID: 26314875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study.
    Borggreve AS; van Rossum PSN; Mook S; Haj Mohammad N; van Hillegersberg R; Ruurda JP
    Eur J Surg Oncol; 2019 Oct; 45(10):1919-1925. PubMed ID: 30975447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial.
    Omloo JM; Lagarde SM; Hulscher JB; Reitsma JB; Fockens P; van Dekken H; Ten Kate FJ; Obertop H; Tilanus HW; van Lanschot JJ
    Ann Surg; 2007 Dec; 246(6):992-1000; discussion 1000-1. PubMed ID: 18043101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.
    Koen Talsma A; Shapiro J; Looman CW; van Hagen P; Steyerberg EW; van der Gaast A; van Berge Henegouwen MI; Wijnhoven BP; van Lanschot JJ; ; Hulshof MC; van Laarhoven HW; Nieuwenhuijzen GA; Hospers GA; Bonenkamp JJ; Cuesta MA; Blaisse RJ; Busch OR; ten Kate FJ; Creemers GJ; Punt CJ; Plukker JT; Verheul HM; van Dekken H; van der Sangen MJ; Rozema T; Biermann K; Beukema JC; Piet AH; van Rij CM; Reinders JG; Tilanus HW
    Ann Surg; 2014 Nov; 260(5):786-92; discussion 792-3. PubMed ID: 25379850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy.
    Phillips AW; Lagarde SM; Navidi M; Disep B; Griffin SM
    Ann Surg; 2017 Apr; 265(4):750-756. PubMed ID: 27467444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of Lymph Node Response After Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Depypere L; De Hertogh G; Moons J; Provoost AL; Lerut T; Sagaert X; Coosemans W; Van Veer H; Nafteux P
    Ann Thorac Surg; 2021 Dec; 112(6):1847-1854. PubMed ID: 33352178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive chemoradiation or surgery in elderly patients with potentially curable esophageal cancer in the Netherlands: a nationwide population-based study on patterns of care and survival.
    Koëter M; van Putten M; Verhoeven RHA; Lemmens VEPP; Nieuwenhuijzen GAP
    Acta Oncol; 2018 Sep; 57(9):1192-1200. PubMed ID: 29528262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma.
    Franko J; Voynov G; Goldman CD
    Ann Thorac Surg; 2016 Mar; 101(3):1123-30. PubMed ID: 26652139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.
    de Heer EC; Hulshoff JB; Klerk D; Burgerhof JGM; de Groot DJA; Plukker JTM; Hospers GAP
    Ann Surg Oncol; 2017 Jul; 24(7):1811-1820. PubMed ID: 28188501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Modalities for Esophageal Adenocarcinoma in the United States: Trends and Survival Outcomes.
    Di Corpo M; Schlottmann F; Strassle PD; Nurczyk K; Patti MG
    J Laparoendosc Adv Surg Tech A; 2019 Aug; 29(8):989-994. PubMed ID: 31246532
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence and Prognostic Significance of Extramural Venous Invasion in Patients with Locally Advanced Esophageal Cancer.
    Faiz Z; Huijgen LJW; Alqethami HJ; Burgerhof JGM; Kats-Ugurlu G; Plukker JTM
    Ann Surg Oncol; 2018 Jun; 25(6):1588-1597. PubMed ID: 29611027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.